|China type 2 diabetes treatment status survey of treatment pattern of oral drugs users|
|Ji, Linong1; Lu, Juming2; Weng, Jianping3; Jia, Weiping4; Tian, Haoming5; Zhu, Dalong6; Xing, Xiaoping7; Guo, Lixin8|
|关键词||oral drugs treatment type 2 diabetes|
|刊名||JOURNAL OF DIABETES|
|WOS标题词||Science & Technology|
|类目[WOS]||Endocrinology & Metabolism|
|研究领域[WOS]||Endocrinology & Metabolism|
|关键词[WOS]||POSTPRANDIAL HYPERGLYCEMIA ; ANTIDIABETIC DRUGS ; DIAREGIS REGISTRY ; HYPOGLYCEMIA ; MELLITUS ; PREVALENCE ; INHIBITOR ; METFORMIN ; AGENTS ; RISK|
BackgroundThe aim of the present study was to investigate the current status of oral anti-diabetic drug (OAD) therapy in patients with type 2 diabetes and influencing factors in a real-world setting in China.
MethodsA total of 9872 outpatients with type 2 diabetes, who had received OADs (monotherapy or combination therapy) for at least 3 months were recruited in this study. Current antidiabetic treatment regimen and related clinical data were collected from medical records and analyzed.
ResultsThe most common OADs in use were insulin secretagogues (70.2%) such as sulfonylureas (SUs; 42.7%) or glinides (27.5%), followed by metformin (53.7%), -glucosidase inhibitors (35.9%), thiazolidinediones (17.2%), and dipeptidyl peptidase-4 (DPP-4) inhibitors (0.8%). Dual-drug combination therapy was more common (45.4%) than monotherapy (35.8%) and combination therapy with at least three drugs (17.0%). Patients on SU or glinide monotherapy were more likely to alter their treatment frequently (odds ratio [OR], 1.7; 95% CI, 1.38-2.08; P<0.001).
ConclusionsThe status of OAD use in China is varied with a majority of the patients altering their treatment regimen citing poor effectiveness. These observations from a real-world setting may serve as guidance for improving diabetes management in China.
|资助机构||Novartis Pharma, Beijing, China|
|作者单位||1.Peking Univ, Peoples Hosp, Dept Endocrinol, Beijing 100853, Peoples R China|
2.Chinese Peoples Liberat Army Gen Hosp, Dept Endocrinol, Beijing 100044, Peoples R China
3.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Endocrinol, Guangzhou 510275, Guangdong, Peoples R China
4.Shanghai 6th Hosp, Dept Endocrinol, Shanghai, Peoples R China
5.West China Hosp, Dept Endocrinol, Chengdu, Peoples R China
6.Beijing Hosp, Dept Endocrinol, Beijing, Peoples R China
7.Nanjing Drum Tower Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China
8.Beijing Union Med Coll Hosp, Dept Endocrinol, Beijing, Peoples R China
|Ji, Linong,Lu, Juming,Weng, Jianping,et al. China type 2 diabetes treatment status survey of treatment pattern of oral drugs users[J]. JOURNAL OF DIABETES,2015,7(2):166-173.|
|APA||Ji, Linong.,Lu, Juming.,Weng, Jianping.,Jia, Weiping.,Tian, Haoming.,...&Guo, Lixin.(2015).China type 2 diabetes treatment status survey of treatment pattern of oral drugs users.JOURNAL OF DIABETES,7(2),166-173.|
|MLA||Ji, Linong,et al."China type 2 diabetes treatment status survey of treatment pattern of oral drugs users".JOURNAL OF DIABETES 7.2(2015):166-173.|